Clik here to view.
Third Rock Stocks Up With $516M New Fund, Looks to Start 16 Cos
Luke Timmerman Third Rock Ventures has spent the last six years betting big on early stage biotech investing when most other VC firms have been hunkering down or getting out …
View ArticleClik here to view.
Q&A With Bob Tepper on What’s Next for Third Rock Ventures
Luke Timmerman Third Rock Ventures had the biotech industry buzzing yesterday. It raised its third fund, worth $516 million, to invest in early-stage biotech drug, device, and diagnostic companies. …
View ArticleStill Waiting for the Ships to Come in at Third Rock Ventures
Standish Fleming Third Rock Ventures was in the enviable position of turning away some institutional investors when the life sciences venture firm recently closed on $516 million for its third …
View ArticleClik here to view.
Sage Therapeutics Shifts Gears, Focuses on Rare Form of Epilepsy
Ben Fidler Sometimes it takes a little time, and a little luck for a company to find its identity. Of course, when you’re a biotech like Cambridge, MA-based Sage Therapeutics…
View ArticleClik here to view.
Dunsire Returns to Action to Tackle CNS Disorders With EnVivo
Ben Fidler Deborah Dunsire rose to prominence in the biotech industry by leading Millennium Pharmaceuticals through its ascension as an oncology powerhouse. Now, she’s taking a stab at a whole …
View ArticleClik here to view.
Sage Taps Former Shire Exec to Lead CNS Drugs Into Clinical Trials
Ben Fidler Third Rock Ventures has spent close to two years refining the strategy for startup Sage Therapeutics. Now it’s found the management team to execute it. Cambridge, MA-based Sage …
View ArticleClik here to view.
Sage Therapeutics Nabs $20M Series B From Third Rock, Arch
Ben Fidler (Corrected, 10/17/13, 1:21 pm ET) It’s been a busy 2013 for Sage Therapeutics. First, it fine-tuned its strategy. Then it got a $10 million grant and …
View ArticleClik here to view.
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief
Ben Fidler John Maraganore opened up an envelope in 1994 that changed his life. Inside were the results of the pivotal study of an anticoagulant drug Maraganore had created in …
View ArticleClik here to view.
Hear Epizyme, Sage, Zafgen Share Their Stories on Oct. 8
Ben Fidler Like many biotechs with a big idea showing early potential, Cambridge, MA-based Epizyme (NASDAQ: EPZM) faced a critical decision a few years ago: groom itself for a …
View ArticleClik here to view.
One Week to Boston’s Life Science Disruptors—Check Out the Agenda
Editors It’s just one week to our annual fall biotech event—where the founders and lead investors of three of Boston’s hottest companies share their stories of trying to build great …
View Article
